Literature DB >> 6959195

Kinetics of citalopram in man; plasma levels in patients.

K Fredricson Overø.   

Abstract

1. Citalopram is rapidly absorbed and slowly eliminated in man. The kinetics is linear and characterized by systemic and apparent oral clearance values of 0.4 l/min, a theoretical distribution volume of 14 l/kg and a half-life of 1 1/2 days. 2. The steady state plasma levels in 70 patients range from 95 to 720 nM at doses of 30 to 60 mg and agree well with predicted values. The mean level is 245 nM at the standard dose of 40 mg daily. 3. Inter-individual variation is 7-fold and independent of sex and age (21-65 years). The average intra-individual variation is about 15%. Estimates of apparent oral clearance vary from 0.15 to 1.02 l/min. 4. The average concentration ratio between citalopram and its demethylated metabolite is 2.7. The levels of di-demethylated metabolite are negligible.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6959195     DOI: 10.1016/s0278-5846(82)80181-4

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  31 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 2.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

3.  Antidepressant response to chronic citalopram treatment in eight inbred mouse strains.

Authors:  Jianwei Jiao; Angela M Nitzke; Demetrios G Doukas; Mariel P Seiglie; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

4.  The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach.

Authors:  Lena E Friberg; Geoffrey K Isbister; L Peter Hackett; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  A validated spectrofluorimetric method for the determination of citalopram in bulk and pharmaceutical preparations based on the measurement of the silver nanoparticles-enhanced fluorescence of citalopram/terbium complexes.

Authors:  Muhammad Naeem Khan; Jasmin Shah; Muhammad Rasul Jan; Sang Hak Lee
Journal:  J Fluoresc       Date:  2012-09-27       Impact factor: 2.217

6.  In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats.

Authors:  F C Kugelberg; G Apelqvist; B Carlsson; J Ahlner; F Bengtsson
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

7.  Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels.

Authors:  L Bjerkenstedt; L Flyckt; K F Overø; O Lingjaerde
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram.

Authors:  J Hyttel; K F Overø; J Arnt
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results.

Authors:  Silvio R Bareggi; L Bianchi; R Cavallaro; M Gervasoni; F Siliprandi; L Bellodi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.

Authors:  Gerard Honig; Minke E Jongsma; Marieke C G van der Hart; Laurence H Tecott
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.